img

Global Bi-Specific MAbS Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Bi-Specific MAbS Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.
Bi-Specific MAbS report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Bi-Specific MAbS market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Cancer and Autoimmune Diseases are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Bi-Specific MAbS industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Bi-Specific MAbS key companies include Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V. and Daiichi Sankyo Company, etc. Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd. are top 3 players and held % share in total in 2022.
Bi-Specific MAbS can be divided into Catumaxomab, Blinatumomab, Duligotumab and SAR 156597, etc. Catumaxomab is the mainstream product in the market, accounting for % share globally in 2022.
Bi-Specific MAbS is widely used in various fields, such as Cancer, Autoimmune Diseases, Inflammatory Diseases and Infectious Diseases, etc. Cancer provides greatest supports to the Bi-Specific MAbS industry development. In 2022, global % share of Bi-Specific MAbS went into Cancer filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bi-Specific MAbS market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Johnson and Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Chugai Pharmaceutical
Bayer AG
Thermo Fisher Scientific
Bistro-Myers Squibb
Mylan N.V.
Daiichi Sankyo Company
Abbott
AstraZeneca
Eli Lilly
Merck and Co.
Amgen
Pfizer
GlaxoSmithKline plc
Roche
Segment by Type
Catumaxomab
Blinatumomab
Duligotumab
SAR 156597

Segment by Application


Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Microbial Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Bi-Specific MAbS market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Bi-Specific MAbS introduction, etc. Bi-Specific MAbS Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Bi-Specific MAbS market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Bi-Specific MAbS
1.1 Bi-Specific MAbS Market Overview
1.1.1 Bi-Specific MAbS Product Scope
1.1.2 Bi-Specific MAbS Market Status and Outlook
1.2 Global Bi-Specific MAbS Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Bi-Specific MAbS Market Size by Region (2024-2034)
1.4 Global Bi-Specific MAbS Historic Market Size by Region (2024-2024)
1.5 Global Bi-Specific MAbS Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Bi-Specific MAbS Market Size (2024-2034)
1.6.1 North America Bi-Specific MAbS Market Size (2024-2034)
1.6.2 Europe Bi-Specific MAbS Market Size (2024-2034)
1.6.3 Asia-Pacific Bi-Specific MAbS Market Size (2024-2034)
1.6.4 Latin America Bi-Specific MAbS Market Size (2024-2034)
1.6.5 Middle East & Africa Bi-Specific MAbS Market Size (2024-2034)
2 Bi-Specific MAbS Market by Type
2.1 Introduction
2.1.1 Catumaxomab
2.1.2 Blinatumomab
2.1.3 Duligotumab
2.1.4 SAR 156597
2.2 Global Bi-Specific MAbS Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Bi-Specific MAbS Historic Market Size by Type (2024-2024)
2.2.2 Global Bi-Specific MAbS Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Bi-Specific MAbS Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Bi-Specific MAbS Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Bi-Specific MAbS Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Bi-Specific MAbS Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Bi-Specific MAbS Revenue Breakdown by Type (2024-2034)
3 Bi-Specific MAbS Market Overview by Application
3.1 Introduction
3.1.1 Cancer
3.1.2 Autoimmune Diseases
3.1.3 Inflammatory Diseases
3.1.4 Infectious Diseases
3.1.5 Microbial Diseases
3.1.6 Others
3.2 Global Bi-Specific MAbS Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Bi-Specific MAbS Historic Market Size by Application (2024-2024)
3.2.2 Global Bi-Specific MAbS Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Bi-Specific MAbS Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Bi-Specific MAbS Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Bi-Specific MAbS Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Bi-Specific MAbS Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Bi-Specific MAbS Revenue Breakdown by Application (2024-2034)
4 Bi-Specific MAbS Competition Analysis by Players
4.1 Global Bi-Specific MAbS Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2022)
4.3 Date of Key Players Enter into Bi-Specific MAbS Market
4.4 Global Top Players Bi-Specific MAbS Headquarters and Area Served
4.5 Key Players Bi-Specific MAbS Product Solution and Service
4.6 Competitive Status
4.6.1 Bi-Specific MAbS Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Johnson and Johnson
5.1.1 Johnson and Johnson Profile
5.1.2 Johnson and Johnson Main Business
5.1.3 Johnson and Johnson Bi-Specific MAbS Products, Services and Solutions
5.1.4 Johnson and Johnson Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.1.5 Johnson and Johnson Recent Developments
5.2 Novartis AG
5.2.1 Novartis AG Profile
5.2.2 Novartis AG Main Business
5.2.3 Novartis AG Bi-Specific MAbS Products, Services and Solutions
5.2.4 Novartis AG Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.2.5 Novartis AG Recent Developments
5.3 Hoffmann-La Roche Ltd.
5.3.1 Hoffmann-La Roche Ltd. Profile
5.3.2 Hoffmann-La Roche Ltd. Main Business
5.3.3 Hoffmann-La Roche Ltd. Bi-Specific MAbS Products, Services and Solutions
5.3.4 Hoffmann-La Roche Ltd. Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.3.5 Chugai Pharmaceutical Recent Developments
5.4 Chugai Pharmaceutical
5.4.1 Chugai Pharmaceutical Profile
5.4.2 Chugai Pharmaceutical Main Business
5.4.3 Chugai Pharmaceutical Bi-Specific MAbS Products, Services and Solutions
5.4.4 Chugai Pharmaceutical Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.4.5 Chugai Pharmaceutical Recent Developments
5.5 Bayer AG
5.5.1 Bayer AG Profile
5.5.2 Bayer AG Main Business
5.5.3 Bayer AG Bi-Specific MAbS Products, Services and Solutions
5.5.4 Bayer AG Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.5.5 Bayer AG Recent Developments
5.6 Thermo Fisher Scientific
5.6.1 Thermo Fisher Scientific Profile
5.6.2 Thermo Fisher Scientific Main Business
5.6.3 Thermo Fisher Scientific Bi-Specific MAbS Products, Services and Solutions
5.6.4 Thermo Fisher Scientific Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.6.5 Thermo Fisher Scientific Recent Developments
5.7 Bistro-Myers Squibb
5.7.1 Bistro-Myers Squibb Profile
5.7.2 Bistro-Myers Squibb Main Business
5.7.3 Bistro-Myers Squibb Bi-Specific MAbS Products, Services and Solutions
5.7.4 Bistro-Myers Squibb Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.7.5 Bistro-Myers Squibb Recent Developments
5.8 Mylan N.V.
5.8.1 Mylan N.V. Profile
5.8.2 Mylan N.V. Main Business
5.8.3 Mylan N.V. Bi-Specific MAbS Products, Services and Solutions
5.8.4 Mylan N.V. Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.8.5 Mylan N.V. Recent Developments
5.9 Daiichi Sankyo Company
5.9.1 Daiichi Sankyo Company Profile
5.9.2 Daiichi Sankyo Company Main Business
5.9.3 Daiichi Sankyo Company Bi-Specific MAbS Products, Services and Solutions
5.9.4 Daiichi Sankyo Company Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.9.5 Daiichi Sankyo Company Recent Developments
5.10 Abbott
5.10.1 Abbott Profile
5.10.2 Abbott Main Business
5.10.3 Abbott Bi-Specific MAbS Products, Services and Solutions
5.10.4 Abbott Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.10.5 Abbott Recent Developments
5.11 AstraZeneca
5.11.1 AstraZeneca Profile
5.11.2 AstraZeneca Main Business
5.11.3 AstraZeneca Bi-Specific MAbS Products, Services and Solutions
5.11.4 AstraZeneca Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.11.5 AstraZeneca Recent Developments
5.12 Eli Lilly
5.12.1 Eli Lilly Profile
5.12.2 Eli Lilly Main Business
5.12.3 Eli Lilly Bi-Specific MAbS Products, Services and Solutions
5.12.4 Eli Lilly Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.12.5 Eli Lilly Recent Developments
5.13 Merck and Co.
5.13.1 Merck and Co. Profile
5.13.2 Merck and Co. Main Business
5.13.3 Merck and Co. Bi-Specific MAbS Products, Services and Solutions
5.13.4 Merck and Co. Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.13.5 Merck and Co. Recent Developments
5.14 Amgen
5.14.1 Amgen Profile
5.14.2 Amgen Main Business
5.14.3 Amgen Bi-Specific MAbS Products, Services and Solutions
5.14.4 Amgen Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.14.5 Amgen Recent Developments
5.15 Pfizer
5.15.1 Pfizer Profile
5.15.2 Pfizer Main Business
5.15.3 Pfizer Bi-Specific MAbS Products, Services and Solutions
5.15.4 Pfizer Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.15.5 Pfizer Recent Developments
5.16 GlaxoSmithKline plc
5.16.1 GlaxoSmithKline plc Profile
5.16.2 GlaxoSmithKline plc Main Business
5.16.3 GlaxoSmithKline plc Bi-Specific MAbS Products, Services and Solutions
5.16.4 GlaxoSmithKline plc Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.16.5 GlaxoSmithKline plc Recent Developments
5.17 Roche
5.17.1 Roche Profile
5.17.2 Roche Main Business
5.17.3 Roche Bi-Specific MAbS Products, Services and Solutions
5.17.4 Roche Bi-Specific MAbS Revenue (US$ Million) & (2024-2024)
5.17.5 Roche Recent Developments
6 North America
6.1 North America Bi-Specific MAbS Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Bi-Specific MAbS Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific MAbS Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Bi-Specific MAbS Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific MAbS Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Bi-Specific MAbS Market Dynamics
11.1 Bi-Specific MAbS Industry Trends
11.2 Bi-Specific MAbS Market Drivers
11.3 Bi-Specific MAbS Market Challenges
11.4 Bi-Specific MAbS Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Bi-Specific MAbS Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Bi-Specific MAbS Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Bi-Specific MAbS Market Size Share by Region (2024-2024)
Table 4. Global Bi-Specific MAbS Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Bi-Specific MAbS Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Bi-Specific MAbS Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Bi-Specific MAbS Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Bi-Specific MAbS Revenue Market Share by Type (2024-2024)
Table 9. Global Bi-Specific MAbS Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Table 11. North America Bi-Specific MAbS Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Bi-Specific MAbS Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Bi-Specific MAbS Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Bi-Specific MAbS Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Bi-Specific MAbS Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Bi-Specific MAbS Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Bi-Specific MAbS Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Bi-Specific MAbS Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Bi-Specific MAbS Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Bi-Specific MAbS Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Bi-Specific MAbS Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Bi-Specific MAbS Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Bi-Specific MAbS Revenue Market Share by Application (2024-2024)
Table 24. Global Bi-Specific MAbS Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Table 26. North America Bi-Specific MAbS Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Bi-Specific MAbS Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Bi-Specific MAbS Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Bi-Specific MAbS Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Bi-Specific MAbS Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Bi-Specific MAbS Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Bi-Specific MAbS Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Bi-Specific MAbS Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Bi-Specific MAbS Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Bi-Specific MAbS Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Bi-Specific MAbS Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Bi-Specific MAbS Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bi-Specific MAbS as of 2022)
Table 39. Date of Key Players Enter into Bi-Specific MAbS Market
Table 40. Global Bi-Specific MAbS Key Players Headquarters and Area Served
Table 41. Bi-Specific MAbS Product Solution and Service
Table 42. Global Bi-Specific MAbS Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Johnson and Johnson Basic Information List
Table 45. Johnson and Johnson Description and Business Overview
Table 46. Johnson and Johnson Bi-Specific MAbS Products, Services and Solutions
Table 47. Revenue (US$ Million) in Bi-Specific MAbS Business of Johnson and Johnson (2024-2024)
Table 48. Johnson and Johnson Recent Developments
Table 49. Novartis AG Basic Information List
Table 50. Novartis AG Description and Business Overview
Table 51. Novartis AG Bi-Specific MAbS Products, Services and Solutions
Table 52. Revenue (US$ Million) in Bi-Specific MAbS Business of Novartis AG (2024-2024)
Table 53. Novartis AG Recent Developments
Table 54. Hoffmann-La Roche Ltd. Basic Information List
Table 55. Hoffmann-La Roche Ltd. Description and Business Overview
Table 56. Hoffmann-La Roche Ltd. Bi-Specific MAbS Products, Services and Solutions
Table 57. Revenue (US$ Million) in Bi-Specific MAbS Business of Hoffmann-La Roche Ltd. (2024-2024)
Table 58. Hoffmann-La Roche Ltd. Recent Developments
Table 59. Chugai Pharmaceutical Basic Information List
Table 60. Chugai Pharmaceutical Description and Business Overview
Table 61. Chugai Pharmaceutical Bi-Specific MAbS Products, Services and Solutions
Table 62. Revenue (US$ Million) in Bi-Specific MAbS Business of Chugai Pharmaceutical (2024-2024)
Table 63. Chugai Pharmaceutical Recent Developments
Table 64. Bayer AG Basic Information List
Table 65. Bayer AG Description and Business Overview
Table 66. Bayer AG Bi-Specific MAbS Products, Services and Solutions
Table 67. Revenue (US$ Million) in Bi-Specific MAbS Business of Bayer AG (2024-2024)
Table 68. Bayer AG Recent Developments
Table 69. Thermo Fisher Scientific Basic Information List
Table 70. Thermo Fisher Scientific Description and Business Overview
Table 71. Thermo Fisher Scientific Bi-Specific MAbS Products, Services and Solutions
Table 72. Revenue (US$ Million) in Bi-Specific MAbS Business of Thermo Fisher Scientific (2024-2024)
Table 73. Thermo Fisher Scientific Recent Developments
Table 74. Bistro-Myers Squibb Basic Information List
Table 75. Bistro-Myers Squibb Description and Business Overview
Table 76. Bistro-Myers Squibb Bi-Specific MAbS Products, Services and Solutions
Table 77. Revenue (US$ Million) in Bi-Specific MAbS Business of Bistro-Myers Squibb (2024-2024)
Table 78. Bistro-Myers Squibb Recent Developments
Table 79. Mylan N.V. Basic Information List
Table 80. Mylan N.V. Description and Business Overview
Table 81. Mylan N.V. Bi-Specific MAbS Products, Services and Solutions
Table 82. Revenue (US$ Million) in Bi-Specific MAbS Business of Mylan N.V. (2024-2024)
Table 83. Mylan N.V. Recent Developments
Table 84. Daiichi Sankyo Company Basic Information List
Table 85. Daiichi Sankyo Company Description and Business Overview
Table 86. Daiichi Sankyo Company Bi-Specific MAbS Products, Services and Solutions
Table 87. Revenue (US$ Million) in Bi-Specific MAbS Business of Daiichi Sankyo Company (2024-2024)
Table 88. Daiichi Sankyo Company Recent Developments
Table 89. Abbott Basic Information List
Table 90. Abbott Description and Business Overview
Table 91. Abbott Bi-Specific MAbS Products, Services and Solutions
Table 92. Revenue (US$ Million) in Bi-Specific MAbS Business of Abbott (2024-2024)
Table 93. Abbott Recent Developments
Table 94. AstraZeneca Basic Information List
Table 95. AstraZeneca Description and Business Overview
Table 96. AstraZeneca Bi-Specific MAbS Products, Services and Solutions
Table 97. Revenue (US$ Million) in Bi-Specific MAbS Business of AstraZeneca (2024-2024)
Table 98. AstraZeneca Recent Developments
Table 99. Eli Lilly Basic Information List
Table 100. Eli Lilly Description and Business Overview
Table 101. Eli Lilly Bi-Specific MAbS Products, Services and Solutions
Table 102. Revenue (US$ Million) in Bi-Specific MAbS Business of Eli Lilly (2024-2024)
Table 103. Eli Lilly Recent Developments
Table 104. Merck and Co. Basic Information List
Table 105. Merck and Co. Description and Business Overview
Table 106. Merck and Co. Bi-Specific MAbS Products, Services and Solutions
Table 107. Revenue (US$ Million) in Bi-Specific MAbS Business of Merck and Co. (2024-2024)
Table 108. Merck and Co. Recent Developments
Table 109. Amgen Basic Information List
Table 110. Amgen Description and Business Overview
Table 111. Amgen Bi-Specific MAbS Products, Services and Solutions
Table 112. Revenue (US$ Million) in Bi-Specific MAbS Business of Amgen (2024-2024)
Table 113. Amgen Recent Developments
Table 114. Pfizer Basic Information List
Table 115. Pfizer Description and Business Overview
Table 116. Pfizer Bi-Specific MAbS Products, Services and Solutions
Table 117. Revenue (US$ Million) in Bi-Specific MAbS Business of Pfizer (2024-2024)
Table 118. Pfizer Recent Developments
Table 119. GlaxoSmithKline plc Basic Information List
Table 120. GlaxoSmithKline plc Description and Business Overview
Table 121. GlaxoSmithKline plc Bi-Specific MAbS Products, Services and Solutions
Table 122. Revenue (US$ Million) in Bi-Specific MAbS Business of GlaxoSmithKline plc (2024-2024)
Table 123. GlaxoSmithKline plc Recent Developments
Table 124. Roche Basic Information List
Table 125. Roche Description and Business Overview
Table 126. Roche Bi-Specific MAbS Products, Services and Solutions
Table 127. Revenue (US$ Million) in Bi-Specific MAbS Business of Roche (2024-2024)
Table 128. Roche Recent Developments
Table 129. North America Bi-Specific MAbS Market Size by Country (2024-2024) & (US$ Million)
Table 130. North America Bi-Specific MAbS Market Size by Country (2024-2034) & (US$ Million)
Table 131. Europe Bi-Specific MAbS Market Size by Country (2024-2024) & (US$ Million)
Table 132. Europe Bi-Specific MAbS Market Size by Country (2024-2034) & (US$ Million)
Table 133. Asia-Pacific Bi-Specific MAbS Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 134. Asia-Pacific Bi-Specific MAbS Market Size by Region (2024-2024) & (US$ Million)
Table 135. Asia-Pacific Bi-Specific MAbS Market Size by Region (2024-2034) & (US$ Million)
Table 136. Asia-Pacific Bi-Specific MAbS Market Share by Region (2024-2024)
Table 137. Asia-Pacific Bi-Specific MAbS Market Share by Region (2024-2034)
Table 138. Latin America Bi-Specific MAbS Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 139. Latin America Bi-Specific MAbS Market Size by Country (2024-2024) & (US$ Million)
Table 140. Latin America Bi-Specific MAbS Market Size by Country (2024-2034) & (US$ Million)
Table 141. Middle East & Africa Bi-Specific MAbS Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 142. Middle East & Africa Bi-Specific MAbS Market Size by Country (2024-2024) & (US$ Million)
Table 143. Middle East & Africa Bi-Specific MAbS Market Size by Country (2024-2034) & (US$ Million)
Table 144. Bi-Specific MAbS Market Trends
Table 145. Bi-Specific MAbS Market Drivers
Table 146. Bi-Specific MAbS Market Challenges
Table 147. Bi-Specific MAbS Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bi-Specific MAbS Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Bi-Specific MAbS Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Bi-Specific MAbS Market Share by Regions: 2022 VS 2034
Figure 4. Global Bi-Specific MAbS Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Bi-Specific MAbS Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Bi-Specific MAbS Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Bi-Specific MAbS Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Bi-Specific MAbS Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Bi-Specific MAbS Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Catumaxomab
Figure 11. Global Catumaxomab Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Blinatumomab
Figure 13. Global Blinatumomab Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Duligotumab
Figure 15. Global Duligotumab Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of SAR 156597
Figure 17. Global SAR 156597 Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Global Bi-Specific MAbS Market Size Share by Type: 2022 & 2034
Figure 19. North America Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Figure 20. Europe Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Figure 21. Asia-Pacific Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Figure 22. Latin America Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Figure 23. Middle East and Africa Bi-Specific MAbS Revenue Market Share by Type (2024-2034)
Figure 24. Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 25. Autoimmune Diseases Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 26. Inflammatory Diseases Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 27. Infectious Diseases Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 28. Microbial Diseases Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 29. Others Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 30. Global Bi-Specific MAbS Market Size Share by Application: 2022 & 2034
Figure 31. North America Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Figure 32. Europe Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Figure 33. Asia-Pacific Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Figure 34. Latin America Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Figure 35. Middle East and Africa Bi-Specific MAbS Revenue Market Share by Application (2024-2034)
Figure 36. Bi-Specific MAbS Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 37. Global Top 5 and Top 10 Players Bi-Specific MAbS Market Share in 2022
Figure 38. North America Bi-Specific MAbS Market Share by Country (2024-2034)
Figure 39. United States Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 40. Canada Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 41. Germany Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 42. France Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 43. U.K. Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 44. Italy Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 45. Russia Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 46. Nordic Countries Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 47. Asia-Pacific Bi-Specific MAbS Market Share by Region (2024-2034)
Figure 48. China Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 49. Japan Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 50. South Korea Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 51. Southeast Asia Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 52. India Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 53. Australia Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 54. Latin America Bi-Specific MAbS Market Share by Country (2024-2034)
Figure 55. Mexico Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 56. Brazil Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 57. Middle East & Africa Bi-Specific MAbS Market Share by Country (2024-2034)
Figure 58. Turkey Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 59. Saudi Arabia Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 60. UAE Bi-Specific MAbS Market Size (2024-2034) & (US$ Million)
Figure 61. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries